| Literature DB >> 30725363 |
Fabio Massimo Perrotta1, Silvia Scriffignano1, Antonia De Socio1, Ennio Lubrano2.
Abstract
INTRODUCTION: The present study aimed (a) to evaluate the clinical and radiographic characteristics of hand erosive osteoarthritis (EOA) in a group of consecutive patients, (b) to correlate the severity of radiographic involvement with clinical and laboratory findings and (c) to associate the levels of pain and functional impairment with some radiographic findings.Entities:
Keywords: Clinical assessment; Erosive; Imaging; Osteoarthritis; Outcome
Year: 2019 PMID: 30725363 PMCID: PMC6393271 DOI: 10.1007/s40744-019-0145-7
Source DB: PubMed Journal: Rheumatol Ther ISSN: 2198-6576
Clinical, laboratory and radiographic features of the patients (n = 60) with erosive osteoarthritis
| Male/female | 13:47 |
| Mean age (SD), years | 66.4 (7.7) |
| Symptoms duration, mean (SD), years | 7.9 (5.4) |
| Body mass index, median (IQR) | 25.48 (22.5–29.2) |
| Smoking (current/past), | 15 (25) |
| Pain on VAS (median/IQR) | 55 (37.5–75.5) |
| PtGA on VAS (median/IQR) | 31 (50–60) |
| Tender joints (median/IQR) | 4 (2–8) |
| Clinically active (swollen) joints (median/IQR) | 1 (0–2) |
| Presence of joint with limited range of motion/ankylosis (at least one), | 25 (41.6) |
| HAQ (median/IQR) | 0.75 (0.37–1.06) |
| AUSCAN, median (IQR) (0–60) | 33.1 (21–43) |
| Presence of comorbidity (any), | 45 (75) |
| C-reactive protein (median/IQR), mg/L | 2 (2–4) |
| Serum vitamin D (median/IQR), μg/L | 32.2 (15.2–38.9) |
| Treatment | |
| Classical NSAIDs (including acetaminophen), | 22 (36.7) |
| COX-2 inhibitors, | 18 (30) |
| Glucosamine, | 17 (28.3) |
| Chondroitin sulfate, | 8 (13.3) |
| Hydroxychloroquine, | 3 (5) |
| Kallman radiographic score (median/IQR) | 39.5 (35–47.5) |
VAS visual analogue scale, SD standard deviation, IQR interquartile range, PtGA patient global assessment, HAQ Health Assessment Questionnaire, AUSCAN Australian Canadian Osteoarthritis Hand Index, NSAIDs non-steroidal anti-inflammatory drugs, COX-2 cyclooxygenase-2
Fig. 1Number of patients with each x-ray finding according to Verbruggen–Veys in the right (a) and left (b) hand. N normal, S stationary (only OA findings with space narrowing), J joint space disappearance, E presence of erosions, R remodelling
Correlation of Kallman’s score, number of erosion at each joint site, number of osteophytes at each joint site and presence of joint space narrowing at each joint site with the different clinical and laboratory variables
| Kallman score | Erosions | Osteophytes | Joint space narrowing | |||||
|---|---|---|---|---|---|---|---|---|
| Spearman ( | Spearman ( | Spearman ( | Spearman ( | |||||
| Age | 0.22 | NS | 0.15 | NS | 0.27 | 0.04 | 0.23 | NS |
| Body mass index | 0.02 | NS | 0.12 | NS | 0.01 | NS | 0.01 | NS |
| Symptoms duration | 0.41 | 0.001 | 0.20 | NS | 0.45 | 0.001 | 0.39 | 0.003 |
| Pain on VAS | 0.16 | NS | 0.17 | NS | 0.27 | 0.04 | 0.14 | NS |
| PtGA on VAS | 0.12 | NS | 0.15 | NS | 0.1 | NS | 0.11 | NS |
| Tender joints | 0.17 | NS | 0.27 | 0.04 | 0.26 | 0.05 | 0.1 | NS |
| Clinically active (swollen) joints | 0.34 | 0.01 | 0.03 | NS | 0.43 | 0.001 | 0.35 | 0.009 |
| HAQ | 0.30 | 0.02 | 0.13 | NS | 0.40 | 0.002 | 0.27 | 0.04 |
| AUSCAN | 0.33 | 0.01 | 0.20 | NS | 0.42 | 0.01 | 0.24 | NS |
| C-reactive protein, mg/L | 0.11 | NS | 0.02 | NS | 0.06 | NS | 0.11 | NS |
VAS visual analogue scale, PtGA patient global assessment, HAQ Health Assessment Questionnaire, AUSCAN Australian Canadian Osteoarthritis Hand Index, NS not significant
Association (odd ratio/95% CI) of pain on VAS, presence of joints with limited range of motion/ankylosis, function (AUSCAN) and quality of life (HAQ) with the localization of more severe disease (“E” or “R” phase)
| Proximal IP joint involvement | Distal IP joint involvement | |||
|---|---|---|---|---|
| Odd ratio (95% CI) | Odd ratio (95% CI) | |||
| Pain in VAS (> 50 mm vs ≤ 50 mm) | 1.3 (0.45–4.05) | NS | 1.9 (0.4–8.9) | NS |
| Joints with limited range of motion/ankylosis (presence vs absence) | 4.34 (1.34–14.3) | 0.01 | 1.33 (0.28–6.26) | NS |
| AUSCAN (> 30 vs ≤ 30) | 5.33 (1.59–17.8) | 0.001 | 4.94 (0.89–27.31) | NS |
| HAQ (> 0.5 vs ≤ 0.5) | 4.54 (1.37–15.07) | 0.01 | 3.02 (0.63–14.38) | NS |
VAS visual analogue scale, AUSCAN Australian Canadian Osteoarthritis Hand Index, HAQ Health Assessment Questionnaire